LAMIVUDINE, NEVIRAPINE, AND STAVUDINE
Pre-Launchlamivudine, nevirapine, and stavudine
NDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing lamivudine, nevirapine, and stavudine—three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection. The combination works by inhibiting viral reverse transcriptase, reducing viral replication and allowing immune recovery. This product is in pre-launch stage and represents a simplified, multi-drug regimen approach to antiretroviral therapy.
Pre-Launch
Pre-launch stage indicates early commercial planning; team will likely focus on regulatory preparation, market access strategy, and payer alignment before launch.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children
Started Dec 2006
44 enrolled
HIV Infections
Career Relevance
This pre-launch product offers career opportunities in regulatory navigation, market access negotiation, and launch planning—ideal for professionals seeking to build expertise in generic-competitive markets and resource-limited healthcare systems. Working on this product means developing skills in cost-based positioning, payer strategy, and global access programs rather than premium brand marketing.
Regulatory Affairs Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.